<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03685578</url>
  </required_header>
  <id_info>
    <org_study_id>CNV_2017_02</org_study_id>
    <nct_id>NCT03685578</nct_id>
  </id_info>
  <brief_title>EmboTrap® Revascularization Device Post Market Registry</brief_title>
  <acronym>EXCELLENT</acronym>
  <official_title>Embotrap eXtraction &amp; Clot EvaLuation &amp; Lesion Evaluation for NeuroThrombectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuravi Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neuravi Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A post-market registry evaluating the EmboTrap® Revascularization Device in acute ischemic
      stroke patients with confirmed intracranial large vessel occlusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to assess the efficacy of the EmboTrap® Revascularization
      Device in a real-world setting, as well as to explore correlations between patient
      comorbidities, clot characteristics, revascularization rates, and clinical outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Successful Revascularization</measure>
    <time_frame>1 day</time_frame>
    <description>Assess cerebral revascularization using the modified Thrombolysis in Cerebral Infarction (mTICI) score at the end of the procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-Cause Mortality</measure>
    <time_frame>90 days</time_frame>
    <description>Summary of all mortality regardless of cause at 90 days post-procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic Intracerebral Hemorrhage</measure>
    <time_frame>24 hours</time_frame>
    <description>Rate of intracranial hemorrhage as detected by brain imaging (CT/MR) measured 24 hours after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Independence</measure>
    <time_frame>90 days</time_frame>
    <description>Modified Rankin Scale (mRS) of ≤ 2
Modified Rankin Score (Scale from 0-6):
0 - No symptoms.
- No significant disability. Able to carry out all usual activities, despite some symptoms.
- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.
- Moderate disability. Requires some help, but able to walk unassisted.
- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.
- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.
- Dead</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Cerebral Stroke</condition>
  <arm_group>
    <arm_group_label>Mechanical Thrombectomy</arm_group_label>
    <description>EmboTrap® Revascularization Device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EmboTrap® Revascularization Device</intervention_name>
    <description>EmboTrap® Revascularization Device</description>
    <arm_group_label>Mechanical Thrombectomy</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      thrombus / clot
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Acute Ischemic Stroke patients with confirmed intracranial Large Vessel Occlusion.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18

          2. The subject or the subject's legally authorized representative has signed and dated an
             Informed Consent Form

          3. Subjects experiencing acute ischemic stroke with angiographic confirmation of Large
             Vessel Occlusion (LVO)

          4. A clinical decision has been made to use the EmboTrap® Revascularization Device
             independently and prior to enrollment in the research study.

          5. EmboTrap® Revascularization Device is the first attempted device/technique for
             mechanical thrombectomy for the intracranial occlusion in the subject.

        Exclusion Criteria:

          1. Currently participating in an investigational (drug, device, etc) clinical trial that
             may confound study endpoints. Patients in observational, natural history, and/or
             epidemiological studies not involving intervention are eligible.

          2. Confirmation of positive pregnancy test according to site specific standard of care
             (e.g. test, verbal communication)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adnan Siddiqui, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University at Buffalo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tommy Andersson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AZ Groeninge/ Karolinska University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raul G Nogueira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grady Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Alojipan</last_name>
    <phone>949-789-3964</phone>
    <email>JAlojipa@its.jnj.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lyerly Neurosurgery Baptist Health</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ricardo Hanel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Neurology Institute</name>
      <address>
        <city>Elizabethtown</city>
        <state>Kentucky</state>
        <zip>42701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shervin Dashti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Geisinger</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chelsie Derr</last_name>
      <email>cmderr1@geisinger.edu</email>
    </contact>
    <investigator>
      <last_name>Clemens Schirmer, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 7, 2018</study_first_submitted>
  <study_first_submitted_qc>September 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2018</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mechanical thrombectomy, EmboTrap</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

